Ishika Mahajan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ishika Mahajan has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Aruni Ghose
Cardio-Oncology Service, University College London Hospitals NHS Foundation Trust, London NW1 2PG, UK
2 shared publications - Elisabet Sanchez
Department of Medical Oncology, Medway NHS Foundation Trust, Windmill Road, Gillingham ME7 5NY, UK
2 shared publications - Stergios Boussios
Department of Medical Oncology, Ioannina University Hospital, 45500 Ioannina, Greece
2 shared publications - Abhinanda Pal
Department of Internal Medicine, IQ City Medical College and Narayana Hospital, Durgapur 713206, India
1 shared publication - Anita Bolina
Department of Medical Oncology, Clatterbridge Cancer Centre, Clatterbridge Cancer Centre NHS Foundation Trust, Liverpool CH63 4JY, UK
1 shared publication Anjana Vinod
Mangalore Manipal Acad Higher Sci, Kasturba Med Coll, Dept Med Oncol, Manipal 575001, India
1 shared publication
Latest Publications
- Open Access
- 16 March 2023
- Published by Ecancer Global Foundation in ecancermedicalscience
- Vol. 17, 1-7
Primary neuroendocrine breast cancer—an unusual occurrence
Primary neuroendocrine breast cancer—an unusual occurrence Anjana Vinod1, Ishika Mahajan1,2, Aruni Ghose3,4,5,6 and Saraswathy Sreeram7 1Department of M
- 16 March 2023
- Published by Ecancer Global Foundation in ecancermedicalscience
- Vol. 17, 1-7
Open AccessPrimary neuroendocrine breast cancer—an unusual occurrence
Primary neuroendocrine breast cancer—an unusual occurrence Anjana Vinod1, Ishika Mahajan1,2, Aruni Ghose3,4,5,6 and Saraswathy Sreeram7 1Department of M
- Open Access
- 23 September 2022
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 19 (19) , 12057
Hereditary Ovarian Cancer: Towards a Cost-Effective Prevention Strategy
Ovarian cancer (OC) is the most lethal gynaecological malignancy. The search for a widely affordable and accessible screening strategy to reduce mortality from OC is still ongoing. This coupled with the late-stage presentation and poor prognosis harbours significant health-economic implications. OC is also the most heritable of all cancers, with an estimated 25% of cases having a hereditary predisposition. Advancements in technology have detected multiple mutations, with the majority affecting the BRCA1 and/or BRCA2 genes. Women with BRCA mutations are at a significantly increased lifetime risk of developing OC, often presenting with a high-grade serous pathology, which is associated with higher mortality due to its aggressive characteristic. Therefore, a targeted, cost-effective approach to prevention is paramount to improve clinical outcomes and mortality. Current guidelines offer multiple preventive strategies for individuals with hereditary OC (HOC), including genetic counselling to identify the high-risk women and risk-reducing interventions (RRI), such as surgical management or chemoprophylaxis through contraceptive medications. Evidence for sporadic OC is abundant as compared to the existing dearth in the hereditary subgroup. Hence, our review article narrates an overview of HOC and explores the RRI developed over the years. It attempts to compare the cost effectiveness of these strategies with women of the general population in order to answer the crucial question: what is the most prudent clinically and economically effective strategy for prevention amongst high-risk women?
- 23 September 2022
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 19 (19) , 12057
Open AccessHereditary Ovarian Cancer: Towards a Cost-Effective Prevention Strategy
Ovarian cancer (OC) is the most lethal gynaecological malignancy. The search for a widely affordable and accessible screening strategy to reduce mortality from OC is still ongoing. This coupled with the late-stage presentation and poor prognosis harbours significant health-economic implications. OC is also the most heritable of all cancers, with an estimated 25% of cases having a hereditary predisposition. Advancements in technology have detected multiple mutations, with the majority affecting the BRCA1 and/or BRCA2 genes. Women with BRCA mutations are at a significantly increased lifetime risk of developing OC, often presenting with a high-grade serous pathology, which is associated with higher mortality due to its aggressive characteristic. Therefore, a targeted, cost-effective approach to prevention is paramount to improve clinical outcomes and mortality. Current guidelines offer multiple preventive strategies for individuals with hereditary OC (HOC), including genetic counselling to identify the high-risk women and risk-reducing interventions (RRI), such as surgical management or chemoprophylaxis through contraceptive medications. Evidence for sporadic OC is abundant as compared to the existing dearth in the hereditary subgroup. Hence, our review article narrates an overview of HOC and explores the RRI developed over the years. It attempts to compare the cost effectiveness of these strategies with women of the general population in order to answer the crucial question: what is the most prudent clinically and economically effective strategy for prevention amongst high-risk women?
- Open Access
- 10 July 2022
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 12 (7) , 1119
COVID-19, Mucormycosis and Cancer: The Triple Threat—Hypothesis or Reality?
COVID-19 has been responsible for widespread morbidity and mortality worldwide. Invasive mucormycosis has death rates scaling 80%. India, one of the countries hit worst by the pandemic, is also a hotbed with the highest death rates for mucormycosis. Cancer, a ubiquitously present menace, also contributes to higher case fatality rates. All three entities studied here are individual, massive healthcare threats. The danger of one disease predisposing to the other, the poor performance status of patients with all three diseases, the impact of therapeutics for one disease on the pathology and therapy of the others all warrant physicians having a better understanding of the interplay. This is imperative so as to effectively establish control over the individual patient and population health. It is important to understand the interactions to effectively manage all three entities together to reduce overall morbidity. In this review article, we search for an inter-relationship between the COVID-19 pandemic, emerging mucormycosis, and the global giant, cancer.
- 10 July 2022
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 12 (7) , 1119
Open AccessCOVID-19, Mucormycosis and Cancer: The Triple Threat—Hypothesis or Reality?
COVID-19 has been responsible for widespread morbidity and mortality worldwide. Invasive mucormycosis has death rates scaling 80%. India, one of the countries hit worst by the pandemic, is also a hotbed with the highest death rates for mucormycosis. Cancer, a ubiquitously present menace, also contributes to higher case fatality rates. All three entities studied here are individual, massive healthcare threats. The danger of one disease predisposing to the other, the poor performance status of patients with all three diseases, the impact of therapeutics for one disease on the pathology and therapy of the others all warrant physicians having a better understanding of the interplay. This is imperative so as to effectively establish control over the individual patient and population health. It is important to understand the interactions to effectively manage all three entities together to reduce overall morbidity. In this review article, we search for an inter-relationship between the COVID-19 pandemic, emerging mucormycosis, and the global giant, cancer.